This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
by Urbi Guha
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
BSXNegative Net Change LIVNNegative Net Change NPCEPositive Net Change
medical medical-devices
HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
by Debanjana Dey
Hims & Hers and Tempus AI are taking different paths in AI-driven healthcare, but which stock offers stronger upside now? Let's dive in.
HIMSPositive Net Change TEMPositive Net Change
medical
Do Options Traders Know Something About LifeVantage Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to LFVN stock based on the movements in the options market lately.
LFVNPositive Net Change
medical
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
by Ahan Chakraborty
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
AZNNegative Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
by Ahan Chakraborty
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
AZNNegative Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
by Ahan Chakraborty
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
AZNNegative Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?
by Indrajit Bandyopadhyay
CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised outlook, and broader expansion may set it apart.
CAHNegative Net Change CORNegative Net Change
medical medical-devices
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
by Zacks Equity Research
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
IARTNo Net Change GMEDNegative Net Change PAHCNegative Net Change VCYTPositive Net Change
medical
Is Molina Healthcare Worth Buying at a Premium 26.83X P/E Valuation?
by Zacks Equity Research
MOH's premium valuation reflects confidence in growth, acquisitions and cash strength, even as elevated medical costs pressure margins.
MOHPositive Net Change CNCPositive Net Change JYNTPositive Net Change INDVNegative Net Change
insurance medical
PODD and Omnipod 5: What's Driving Insulet's 2026 Growth
by Sridatri Sarkar
Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.
MDTNegative Net Change DXCMNegative Net Change PODDNegative Net Change
medical